Trial Profile
AIO KRK-0114 / FIRE-4 Avelumab: Randomised study of the efficacy of cetuximab rechallenge in patients with RAS wild-type mCRC responding to an induction treatment in first-line with FOLFIRI plus cetuximab followed by a maintenance concept with either avelumab or 5-FU plus bevacizumab or continuation of FOLFIRI plus cetuximab
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Avelumab; Bevacizumab; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Regorafenib
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms AIO KRK-0114/FIRE-4 Avelumab; FIRE-4
- 13 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 30 Sep 2023 Planned number of patients changed from 673 to 700.
- 06 Jun 2023 Results (n=540) deriving baseline liquid biopsy to analyze RAS and BRAF mutations, presented at the 59th Annual Meeting of the American Society of Clinical Oncology